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Over the last decade many reports
have appeared on the possibilities of
ultrasound for prenatal detection of con-
genital heart disease, but few authors have
tried to assess the actual yield of a
screening program for cardiac anoma-
lies.'-'5 It is important to distinguish
between a limited screening procedure
offered routinely to all pregnant women
(population approach) and extensive fetal
echocardiography offered to those at
(high) risk for fetal congenital heart
disease.
In the population approach, all preg-
nant women undergo routine ultrasound
examination at a certain optimal gesta-
tional age. When a congenital anomaly is
suspected, referral to establish a diagnosis
and appropriate obstetric policy follows.
The screening procedure currently advo-
cated for routine evaluation of the fetal
heart is the four-chamber view at 16 to 24
weeks of pregnancy.3.6
The high-risk approach is generally
accepted and offers extensive fetal echo-
cardiography to selected women, in par-
ticular to those women with a history of
congenital heart disease in their offspring
or those who appear during routine
screening to be carrying an affected
fetus.'16 Anomalies encountered in the
high-risk group tend to be more serious
and complex. In addition to the four-
chamber view, the cardiac connections
and functional status are evaluated.'16
Obviously, this can only be accomplished
by skilled experts during a lengthy and
detailed examination.
To justify routine prenatal screening
in low-risk pregnancies with subsequent
extensive ultrasound examination in case
of suspected fetal pathology, an assess-
ment of the efficiency of such a program is
needed. Presently, however, a favorable
effect of routine fetal ultrasound including
a four-chamber view evaluation is as-
sumed. Routine fetal ultrasound is now
offered to the majority of pregnant women
in several countries, including the Nether-
lands. To our knowledge, this policy has
not been preceded by an appropriate
evaluation. Medical decision analysis of-
fers a possibility for integrating and
analyzing the influence of the efficacy of
screening, the risks for the affected fetus,
and societal or parental attitudes on the
expected distribution of outcomes of
pregnancy in a low-risk population.
We set out to assess whether the
advantages of prenatal detection of car-
diac anomalies by means of ultrasound
examination are sufficiently clear to merit
screening of pregnant women at low risk
for congenital heart disease in their
offspring.
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Methods
Structure of the Model
The present report proceeds from an
inventory of data available in the litera-
ture. These data have been introduced into
a decision analysis model centered on the
problem of whether to offer routine fetal
echocardiography to pregnant women at
low risk. Decision Maker software (New
England Medical Center, Boston, Mass,
1988) was used to structure the model.
The options and chances future parents,
clinicians, and policymakers face at 16 to
24 weeks' gestational age are conveyed
(Figure 1). The high-risk approach as a
separate option was not included in the
model, as its merits have been estab-
lished.6'8"7-20 In addition, as spontaneous
abortion or intrauterine death prior to a
prenatal diagnostic procedure is not ame-
nable to intervention, this possibility was
not evaluated. The probability of an
affected fetus (with minor or major
congenital heart disease) was considered
in the model at the first chance node. The
subsequent chance node in the model
represents routine fetal echocardiography.
Given a malformation in the fetus, the
chance of a positive test result is the
sensitivity. Similarly, the chance of a
negative test given the absence of malfor-
mations is the specificity.
The subsequent branch of the model
represents referral on suspicion of an
anomaly at initial screening. Extensive
fetal echocardiography is offered to those
screened and found to have a suspected
fetal anomaly. Also, those presenting
pregnancy pathology-for example,
growth discrepancy, lack of fetal move-
ments, or abnormal fetal heart rate-are
referred. For the model we assumed that
extensive fetal echocardiography would
in general reveal previous false-positive
diagnostic errors (100% specificity). This
appears to be a reasonable simplification
of the model, since further diagnostic tests
or termination of pregnancy are not
offered unless a (serious) fetal anomaly is
indeed suspected. Nonadoption of screen-
ing implies that extended ultrasound is
available only in the event of clinically
suspected fetal or pregnancy pathology.
Similar to the test characteristics of
routine screening, the test characteristics
of extensive fetal echocardiography have
been applied in the model.
In case an anomaly is confirmed at
extensive fetal ultrasound examination,
chorion villus sampling, amniocentesis, or
cordocentesis is offered. These techniques
have a low risk of induced abortion. This
risk is represented by the corresponding
chance node in the model.
The next step is the decision parents
face when confronted with the diagnosis
and prognosis of their fetus. They may
choose to terminate the pregnancy or
carry to term. Obviously, an unaffected
fetus or a fetus with minor anomalies is
likely to be carried to term. In case the
gestation of a fetus with congenital heart
disease is continued, two outcomes are
possible: intrauterine death or a live infant
with a cardiac anomaly. As a result of the
anomaly the infant may die postnatally.
The risk of a fatal outcome is again
represented by a chance node. The situa-
tion is essentially similar if parents
informed of the presence of a fetal
anomaly decide not to terminate the
pregnancy, if an anomaly is not detected,
or if screening is not offered.
Assignment ofProbabilities
All variables used in the model are
summarized in Table 1. A number of
problems in the assignment of probabili-
ties need to be discussed. An estimate of
the chance of a fetus with congenital heart
disease is preferably based on the preva-
lence of cardiac anomalies at 16 to 24
weeks' gestation. However, while the
prevalence of congenital heart disease at
birth is well documented, reliable esti-
mates at about 20 weeks' gestational age
are sparse. We assumed that newborns
with a birth prevalence of cardiac anoma-
lies of approximately 0.00821 originated
from a larger cohort of fetuses of which a
proportion aborted spontaneously or ended
in premature death. In addition, it should
be noted that only about half of the cardiac
anomalies found in neonates are major
anomalies.22 Assuming that approxi-
mately 37% of the major anomalies end in
premature death,'9'20 the number affected
at 20 weeks' gestation was calculated at
10.3 per 1000 (0.004 + 0.004*1/10.37).
The test characteristics of routine
and extensive ultrasound examination
used in the analysis are based on a
literature survey. Some studies reported
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Note. Top section represents main tree structure with central decision between screening and
no screening. Subsequent sections represent major branches leading to various outcomes.
The letters a through j refer to corresponding probabilities in Table 1.
0 = chance node; 0 = decision node; * = outcome; X = implicit action; minor = minor
anomaly; major = major anomaly; CHD = congenital heart disease; screen = test result of
prenatal ultrasound screening; tertiary = test result of extensive ultrasound examination.
*This chance node could also be represented by a decision node as it is an option (parental)
to terminate pregnancy after detection of a severe anomaly.
FIGURE 1-Outline of the decision model for prenatal ultrasound screening
for congenital disease.
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on a high-risk population and a more
extensive screening procedure, whereas
others reported on a low-risk population
and a simple screening procedure per-
formed once during pregnancy. This
resulted in a wide range of published
results.'-'5 To account for this variability
we assumed the test characteristics, espe-
cially the sensitivity, to vary according to
case severity. Accordingly, the upper
range of sensitivity reported (around
50%) was taken to apply to serious cases,
whereas the lower range of literature
estimates (below 10%) was taken to apply
to minor anomalies. The specificity of
routine screening is reported to be very
high (99%) and has a narrow range. The
sensitivity of extensive fetal ultrasound
evaluation appears to be much better and
has been reported at around 95% with a
narrow range.6.8'17-20 Also, a near 100%
specificity of extensive fetal ultrasound
examination has been reported.68'7-20
Detailed data on extensive fetal echocardi-
ography enabled us to calculate the test
characteristics with the specific indication
of suspected fetal (cardiac) pathol-
ogy.8'9'20 The likelihood of abortion as a
complication of fetal karyotyping is low
(less than 1%).23 Data on the probability
of pregnancy pathology in relation to
congenital heart disease could not be
found. A panel of obstetricians at Rotter-
dam University Hospital estimated the
probability at less than 1%. In case a
malformation is detected parents have to
decide whether to terminate the preg-
nancy. Specific literature on this subject is
scarce. Pryde et al. evaluated several
factors influencing parental decisions re-
garding pregnancy outcome of congeni-
tally malformed offspring.24 The progno-
sis appeared to be of major importance;
two out of three couples opted to termi-
nate pregnancy if a major anomaly was
detected. Termination was never opted for
in case of minor anomalies. Similar
results have been reported in relation to
extensive fetal echocardiography.8' 9.20.24
With regard to the prognosis of
affected fetuses, a distinction between
serious and mild cases was also made.
Cases detected prenatally are likely to be a
subsample with severe anomalies. Accord-
ingly, the outcomes of pregnancy reported
in case-series on cases detected prenatally
are taken to apply to serious cases.
Intrauterine death occurred in 37% of
such cases and infant death in 59%. 1920
On the other hand, children with congeni-
tal heart disease bom alive may represent
a subsample with relatively mild anoma-
lies. Live-bom children with congenital
heart disease have a mortality of less than
10%. This is the estimate of survival used
in the model in case of minor cardiac
malformations. In addition, we assumed
that the majority of minor anomalies do
not cause hemodynamic problems prena-
tally. Accordingly, the fetuses survive to
term. Finally, a sensitivity analysis was
conducted over plausible ranges of the
probabilities (as presented in the right-
hand side of Table 1) to assess the
influence of variability in the estimates on
the outcome of the model.
Results
The impact of routine screening, in
numbers per million second-trimester
pregnancies, is given in Table 2. With an
assumed low sensitivity of 50% for major
anomalies, it is estimated that the number
of children bom with severe congenital
heart disease decreases by a third. A
similar effect on the number of cases of
intrauterine death and neonatal death is
observed. Some of the intrauterine deaths
and neonatal deaths that would otherwise
have occurred are avoided if pregnancy is
terminated in cases detected prenatally.
The impact of routine screening on
the number of children bom with minor
congenital heart disease is negligible. The
number of terminations of pregnancy
would, however, increase 50-fold. Also,
approximately 9900 false-positive screen-
ing tests would result. Moreover, screen-
ing would lead to a loss of 32 fetuses, 28
with major anomalies and 4 with only
minor anomalies, owing to karyotyping.
As we presumed a specificity of extensive
fetal echocardiography of 100%, karyotyp-
ing is not offered to unaffected fetuses. An
increase in sensitivity (to 80% and 20%
for major and minor anomalies, respec-
tively) will reduce the number of cases
with an unfavorable outcome (from 525
fewer to 841 fewer for births of infants
with serious anomalies and from 757
fewer to 1211 fewer for neonatal deaths).
For minor anomalies the change is negli-
gible. Obviously, more pregnancies will
have to be terminated to achieve this
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TABLE 1-Estimates of the Various Probabilities Applied in the Decision Model on Routine Fetal Ultrasound
Examination for Congenital Heart Disease (CHD)
Point Lower Upper
Estimate Value Value Major Anomalies Minor Anomalies
Prevalence2122 0.008 0.003 0.012 0.004 ... 0.004 ...
a. Prenatal prevalencea 0.0103 ... ... 0.0063 ... 0.004 ...
b. Sensitivity routine screening1-15 0.07 0.07 0.50 0.50 (0.20-0.80) 0.07 (0.01-0.20)
c. Specificity routine screening1-15 0.99 0.99 1.0 ... ... ... ...
d. Sensitivity extensive ultrasound68,17-19 0.95 0.927 0.974 ... ... ... ...
e. Specificity extensive ultrasoundb 6.817-19 0.99 0.987 0.993 1.00 ... 1.00 ...
f. Probability abnormal pregnancy given CHD 0.01 ... ... 0.01 (0-0.03) 0.01 (0-0.03)
g. Probability karyotyping induced abortion23 0.01 ... ... ... ...
h. Probability termination of pregnancy given CHD819,20 0.678 0.571 0.773 0.68 (0-1 0) 0.0 ...
i. Probability intra uterine death given CHD'920 0.370 0.194 0.576 0.37 (0.20-0.60) 0.0 ...
j. Probability neonatal death given CHD'9,20 0.588 0.329 0.816 0.59 ... 0.1 ...
Note. In the analysis a distinction is made between major and minor anomalies. The plausible range used in sensitivity analysis is given in
parentheses. Major and minor are categories of congenital malformation according to which sensitivity and clinical course is varied in the model.
Ellipsis points indicate estimates of variables or ranges of variables not examined in the current analysis. The letters a through j refer to
corresponding probabilities in Figure 1.
aExpected prevalence at 20 weeks' gestation calculated; varies according to probability of intrauterine death given CHD.
bin the model a specificity of extensive fetal echocardiography of 100% is applied.
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reduction (from 2005 to 3208). In addi-
tion, as a result of a higher sensitivity, fetal
karyotyping is performed more often,
causing an additional loss of 23 (affected)
fetuses (increasing the number lost from
32 to 55). Also, a sizable number of the
cases that otherwise would have resulted
in intrauterine death or spontaneous abor-
tion are now terminated (from 752 fewer
to 1205 fewer). If sensitivity decreases,
only a marginal effect remains. However,
an identical number of women would
have to be referred and go through an
emotionally difficult period owing to a
false-positive screening test.
Parental inclination toward termina-
tion of pregnancy in case of severe
malformation appears to have an effect
that is numerically comparable to in-
creased sensitivity of routine ultrasound.
Obviously, with an increased proportion
of the parents opting for termination of
pregnancy in case of a major anomaly,
fewer affected neonates are bom. If all
pregnancies are carried to term very little
effect remains.
Figure 2 shows the results of a
two-way sensitivity analysis of the two
major determinants of the impact of
screening. The effect of simultaneously
varying estimates of the sensitivity of
routine fetal ultrasound and estimates of
the proportion of parents opting for
termination of pregnancy, both in case of a
severely affected fetus (i.e., cases result-
ing in neonatal survival with severe
congenital heart disease or cases ending in
neonatal death), is demonstrated. The
number of newboms with serious anoma-
lies prevented increases with increasing
sensitivity and with an increasing probabil-
ity of termination of pregnancy. Sensitiv-
ity and probability of termination show a
combined (multiplicative) effect.
Variation in the probability of abnor-
mal development of pregnancy or preg-
nancy pathology in affected fetuses does
not appear to have any significant impact.
Neither does variation in the probability
of intrauterine death. We assumed the
birth prevalence of congenital heart dis-
ease to remain stable. Accordingly, an
increased probability of premature death
implies that a larger number of pregnan-
cies are terminated that would otherwise
result in intrauterine death. Also, a larger
number of affected fetuses would be lost
owing to karyotyping. (Additional details
and results are obtainable from the au-
thors.)
TABLE 2-Estimated Pregnancy Outcomes of 1 Million Second-Trimester
Pregnancies (Fetuses of 16 to 24 Weeks' Gestational Age)
Outcome No Screening Screening Difference % Changea
Major congenital heart disease 1 629 1 104 -525 -32
Minor congenital heart disease 3 600 3 597 -3 <-0.1
Neonatal death 2 745 1 988 -757 -28
Termination of pregnancy 41 2 046 2 005 49b
Karyotyping-induced abortion 1 33 32 32b
Intrautenne death 2 334 1 582 -752 -32
No congenital heart disease 0 9 897 9897 00b
(false-positive)
No congenital heart disease 989 651 979 754 -9897 -1
aPercentage change relative to no screening.
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FIGURE 2-Results of the two-way sensitivity analysis for the sensitivity of
routine screening for major anomalies and the probability of
termination of pregnancy (impact of screening vs no screening
on number of newborns with serious anomalies prevented).
Discussion
We have shown that routine fetal
ultrasound screening does not meet the
generally held expectations. The funda-
mental idea of screening is that parents,
neonates, and society in general may
benefit from effective screening. One of
the initial assumptions in the model was
that approximately half of all severe
anomalies would be detected prenatally.
On prenatal detection of an anomaly, the
obstetric policy may be adapted. If, for
instance, a case of Fallot's tetralogy with
severe pulmonary stenosis were detected
prenatally, soon after birth the diminished
pulmonary flow could result in a life-
threatening situation. Birth should prefer-
ably take place in a setting able to provide
pediatric intensive care. With prior knowl-
edge, timing, mode, and location of
delivery can be optimized to improve
chances of neonatal survival. In cases
with a (near) fatal prognosis, termination
ofpregnancy presently is the main altema-
tive.7s4 19,20,24-26
According to the model, the birth of
approximately 30% of neonates with
serious congenital heart disease may be
prevented. However, as a consequence 49
times as many pregnancies have to be
terminated, of which again 30% would
have ended in spontaneous abortion. Also,
some affected fetuses will be lost in any
case owing to karyotyping. The hypotheti-
cal yield of routine fetal ultrasound
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appears to be relatively small. Moreover,
in view of recently reported realistic
estimates of the sensitivity of routine fetal
ultrasound, only a few cases with an
unfavorable outcome of pregnancy may
actually be prevented.27 28 Even if optimal
estimates of sensitivity apply, the impact
of prenatal screening for congenital heart
disease on the health of neonates in
general appears limited. This conclusion
is in agreement with that of Nelson et al.,
who reported that a large proportion of
fetal anomalies are not likely to be
diagnosed, especially in a nonreferral
setting.'9 The nature of the anomalies
encountered prenatally predicts, to a large
extent, the possibilities for early detection.
Moreover, routine fetal ultrasound has
additional disadvantages. Even a false-
positive rate of only I % results in a large
number of parents' being told that their
future baby may have congenital heart
disease. If the specificity in reality is 1%
lower, doubling the false-positive rate,
twice as many such cases occur. Apart
from the anxiety caused by such news we
must consider the implications for the
referral institutions. All of these women
will subsequently be referred for exten-
sive ultrasound evaluation. The invest-
ments in personnel, appliances, and clin-
ics required are sizable and revenues are
small.
A second variable that was shown to
affect the attainable yield was the opinion
future parents (or society in general) hold
on termination of pregnancy. The propor-
tion of pregnancies terminated on account
of serious congenital heart disease will
depend strongly on such an opinion or
preference. In other words, the impact of
screening will vary with local legal and
ethical standards and attitudes.
We are aware of the fact that the
basis for some of the other variables
examined was uncertain. However, the
impact of variability of these estimates on
the expected distribution of outcomes of
pregnancy in a low-risk population ap-
peared to be limited. Moreover, the test
characteristics of extensive structural ultra-
sound can already be considered more or
less optimal, as are the complication rates
of fetal karyotyping. Also, the actual
prevalence, the natural history, and factors
affecting the natural history of congenital
malformations are hardly accessible to
intervention. If they were accessible, this
would imply possibilities for primary
prevention.
Finally, an additional remark should
be made regarding the specificity of
extensive fetal echocardiography. The
specificity applied in the model was
presumed to be 100%. Therefore, far-
reaching consequences of false-positive
routine screening tests are absent in the
model and in the results presented. This
may not be quite correct. Recently, cases
have been described of fetuses with
apparently severe congenital heart disease
that proved to have only mild to moderate
anomalies postnatally.30 A false-positive
rate of extensive fetal echocardiography
of 1% (specificity 99%) would result in
approximately 100 such cases (1% of
9897) in the hypothetical cohort. Future
parents erroneously presented with a
serious prognosis who opted to terminate
pregnancy would lose a normal fetus.
Overall, the yield of prenatal screen-
ing for congenital heart disease by means
of the fetal four-chamber view, expressed
as the prevention of the birth of a critically
ill neonate, appears to be numerically
small. With substantial effort the efficacy
of routine screening may be improved.
However, the results would still be
modest. Moreover, the final decision
parents make once a serious fetal anomaly
is detected is culturally, socially, and
economically determined. Evidently, a
generally applicable protocol for termina-
tion of pregnancy is unrealistic.
The significance and valuation of the
cases detected, cases not detected, and
false-positive test results and their subse-
quent outcomes have not been assessed in
the present analysis. Such an assessment
may be attempted by estimating the
psychological relief or burden perceived
by the parents. Additionally, the costs of
screening and postnatal costs could be
weighed against the effects. Heckerling
and Verp23 and Pauker and Pauker3l.32
assigned specific values or utilities to the
various outcomes of pregnancy in a
prenatal Down's syndrome screening pro-
gram. Subsequently the utility of screen-
ing was estimated. Ekwo et al. also
reported on the outcome of pregnancy
with regard to congenital anomalies and
the perceived consequences or burden.33
The parents' opinion on the outcomes of
pregnancy could be expressed on a
preference scale. At present, reliable data
on parental attitudes toward congenital
heart disease are lacking, as are data on
the costs of congenital heart disease. Yet
parental assessment of the various out-
comes may have a substantial impact on
the appreciation and efficiency of a
prenatal screening program for congenital
anomalies. After all, the parents decide
whether or not to have prenatal screening
and how to respond to the outcome of the
test.
In conclusion, routine fetal ultra-
sound screening for congenital heart
disease does not seem warranted at
present. Public health, in particular neona-
tal health, is not likely to improve if
prenatal screening is offered in low-risk
pregnancies. The public expenditures in-
volved could more effectively be spent
otherwise. C:
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